Successful Treatment with Clonazepam and Pramipexole of a Patient with Sleep-Related Eating Disorder Associated with Restless Legs Syndrome: A Case Report by Kobayashi, Nobuyuki et al.
Hindawi Publishing Corporation
Case Reports in Medicine
Volume 2012, Article ID 893681, 4 pages
doi:10.1155/2012/893681
Case Report
SuccessfulTreatmentwith Clonazepam and Pramipexole of
a Patient with Sleep-Related Eating Disorder Associated with
Restless Legs Syndrome: A Case Report
Nobuyuki Kobayashi,1 RyoheiYoshimura,2 andMasahiroTakano3
1Department of Psychosomatic Medicine, Takano Hospital, 4-2-88 Obiyama, Kumamoto 862-0924, Japan
2Oyama Medical Clinic, 6-10-15 Oyama, Kumamoto 861-8045, Japan
3Coloproctology Center, Takano Hospital, 4-2-88 Obiyama, Kumamoto 862-0924, Japan
Correspondence should be addressed to Nobuyuki Kobayashi, n3koba-5zo6pu@nifty.com
Received 20 November 2011; Accepted 22 December 2011
Academic Editor: Linda Gonder-Frederick
Copyright © 2012 Nobuyuki Kobayashi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Sleep-related eating disorder (SRED) is characterized by recurrent episodes of involuntary eating during sleep period and is often
associatedwithrestlesslegs syndrome(RLS).Althoughpharmacotherapy isrecommended forSREDpatients,nodrughaveshown
promising eﬀects so far. The patient, a 48-year-old Japanese housewife, ﬁrst visited our clinic and complained about nighttime eat-
ing.Shehadahistoryofhypertension,diabetesmellitus,sleepapneasyndrome,anddepression.Insomniaappeared10yearsbefore
theﬁrstvisitandsheoftenreceivedhypnosedatives;atthesametime,shedevelopednocturnaleatingepisodes.Shehadamnesiafor
these episodes, and she felt urge to move her legs while sleeping. The patient was diagnosed with SRED and RLS. Reduction in the
doses of triazolam decreased her nighttime eating frequency, and her complete amnesia changed to vague recall of eating during
night. Clonazepam 1.0mg at bedtime decreased nocturnal eating frequency from 1 to 2 times per month, though sleepwalking
remained. Administration of pramipexole 0.125mg relieved all symptoms including SRED, RLS, and sleepwalking. This is the ﬁrst
paper to report that the combination of clonazepam and pramipexole therapy-reduced SRED episodes and RLS symptoms.
1.Introduction
Sleep-related eating disorder (SRED) is characterized by re-
current episodes of involuntary eating and drinking during
the main sleep period. Several patients have amnesia for the
events, and they eat during night usually without hunger or
thirstandatdiﬀerentconsciousnesslevels.Thepatientsoften
eatunpalatablesubstancessuchasfrozenfoodsandcigarettes
[1]. Although the prevalence of this condition is high, nearly
5% in the general population [2], SRED is an un-derrecog-
nized condition by majority of clinicians.
SRED is thought to be a sleep disorder and is distinct
from nocturnal eating disorder (NES) [3]. Patients with NES
exhibit nocturnal hyperphagia, insomnia, and morning ano-
rexia. They are aware of nocturnal arousal and hyperphagia.
SRED is often associated with restless legs syndrome
(RLS) [4]. RLS is a neurological disorder characterized by
an irresistible urge to move the legs, especially at rest. The
symptomsworsenintheeveningandnightandimprovewith
activity such as walking. Besides RLS, SRED is often asso-
ciated with other sleep-related disorders including periodic
limbmovementsofsleep(PLMS),somnambulism,parasom-
nia such as sleepwalking, and sleep apnea syndrome (SAS)
[4].
Pharmacotherapy is recommended for SRED patients
[5]. Although several drugs have been reported to be useful
for SRED patients [5–8], a standard drug has not yet been
found. Pramipexole is shown to be eﬀective in about 75% of
RLS patients [9]. In the patients with SRED, pramipexole de-
creased nocturnal motor activity and improved sleep quality
in a small trial, but it failed to lower the frequency of noctur-
nal eating [6].
We report the case of a patient with SRED and RSL who
received combined treatment of clonazepam and pramipex-
ole that reduced the frequency of night eating as well as the
urge to move legs during sleeping.2 Case Reports in Medicine
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Figure 1: Clinical course. Reduction in the dose of triazolam decreased the freque006Ecy of night eating. Night eating was reduced by
stepwise addition of clonazepam and pramipexole. RLS: restless legs syndrome; Sleepwalking +: present; Sleepwalking −:a b s e n t ;X year
presents the year at ﬁrst visit.
2. Case Presentation
The patient, a 48-year-old Japanese housewife, ﬁrst visited
the psychosomatic clinic and complained of nighttime eat-
ing. She had history of hypertension, type 2 diabetes mellitus
(T2DM), and depression. Insomnia appeared 10 years before
the ﬁrst visit, and she often received hypnosedatives. At
the same time, nocturnal eating episodes developed which
occurred at about half of nights. She ate without hunger and
the eating episodes were often repeated several times in a
night. Sometimes she consumed substances other than foods
such as a soap cake and cooked or ordered foods through
the internet. She had complete amnesia or partial recall of
these episodes and was surprised to ﬁnd the remains of night
eating on the next morning. Five years after the start of these
episodes, the frequency of night eating increased. Further,
her blood glucose level increased without any change in
weight and her snoring increased. She felt the urge to move
her legs while sleeping, which was decreased by physical
movement.
Two years before the ﬁrst visit, she was diagnosed with
sleep apnea syndrome (SAS) and her apnea hypopnea index
was 34.9 (normal range, <5events/h) as shown by pulse ox-
imeter. Treatment with continuous positive airway pressure
was recommended, but she hoped to follow up.
At the ﬁrst visit, her physical examination data was as
follows: height, 155cm; body weight, 55kg; blood pres-
sure, 128/78mmHg. The ophthalmologic and neurological
examination ﬁndings were normal. Urinalysis revealed no
proteinuria, and complete blood cell count was within
the normal limit. Serum chemistry revealed no abnormal-
ities except high fasting blood glucose level (147mg/dL;
normal, <110mg/dL) and high-hemoglobin A1c (HbA1c)
level (7.0%: normal range, 4.4–5.8%). Her hormone proﬁle
was as follows: serum thyroid-stimulating hormone (TSH)
level, 2.0µIU/mL (range: 0.4–4.0µIU/mL); free thyroxine
(fT4) level, 1.0ng/dL (range: 0.8–1.9ng/dL); cortisol level,
18.7µg/dL (range: 3.9–20.6ng/dL).
Psychometric data were as follows. The self-rated depres-
sionscale(SDS)scorewas49(normal,<48).Minnesotamul-
tiphasic personality inventory showed neurotic tendency,
and the subscales were as follows (only T scores ≥70): hyp-
ochondriasis, 78.9; depression, 76.6; hysteria, 73.7. The score
on International Restless Legs Syndrome rating scale (IRLS)
was 31 points (very severe).
She was diagnosed with SRED and RLS, and was advised
to lower the dosage of triazolam from 0.25 to 0.125mg. The
night eating frequency decreased from almost every night to
about a half of the nights, and complete amnesia changed to
vague recall of the night eating (Figure 1).
Then,weincludedclonazepamfrom0.5to1.0mgatbed-
time, which decreased the frequency of nocturnal eating 1
to 2 times per month. However, she continued sleepwalking;
she would stand up or walk about for a few minutes when
aroused. Her urge to move legs was reduced after discontin-
uing triazolam.
In a few months, nocturnal eating frequency increased
up to 5 nights per month and the urge to move legs and
parasomnia also increased. Since she was engaged in caring
for her family members who were undergoing treatment
for some diseases at that time, psychotherapy treatment was
administered to resolve her cognitive behavioral problems.
Clonazepam up to 1.5mg failed to achieve additional im-
provement, and subsequently, pramipexole 0.125mg was
started. Sleepwalking disappeared within two days and night
eating episodes, and the urge to move legs also reduced after
starting pramipexole. The IRLS score was lowered to 13
points (moderate). She has been maintaining this condition
for 10 months and at presentation.Case Reports in Medicine 3
Slight improvement of plasma HbA1c level was observed
immediately after reduction in the night eating episodes. No
apparentimprovementwasfoundafterchangingthedrugfor
T2DM from pioglitazone to sitagliptin. She experienced no
adverse eﬀect.
3. Discussion
In our patient, SRED was improved with 3 steps involving
reduction in the dose of triazolam and subsequent medica-
tion with clonazepam and pramipexole. Many psychotropic
drugs were reported to induce or promote SRED, including
triazolam, amitriptyline, olanzapine, and zolpidem [5, 10–
13]. Discontinuation of triazolam was abandoned because
she felt anxious to stop hypnosedatives.
Clonazepam is eﬀective in some patients with RLS and
is used for treating patients with SRED-associated sleep dis-
orders [5]. Although clonazepam is useful for reducing the
frequency of nocturnal eating with a low response rate, a
combination of dopaminergic agents and clonazepam was
shown to be eﬀective for SRED-associated sleep disorders
with relative high response rate [5]. Clonazepam monother-
apy remarkably decreased the frequency of nocturnal eating
in our patient.
Pramipexole is a dopaminergic agent eﬀective for RLS
and Parkinson’s disease [9], and it has been recently made
available in Japan. Frequent coexistence of SRED and RLS
suggested some relationship between SRED and RSL [14],
and pramipexole was expected to be useful for SRED as
well as RLS. This hypothesis has been previously tested. The
resultsofasmalldouble-blind,placebo-controlledtrialusing
pramipexole in patients with SRED suggested that nocturnal
motor activity recorded by actigraphy was reduced and sub-
jective sleep quality was improved. However, there was no
change in the frequency and duration of waking episodes
related to eating behaviors [6]. In contrast to this paper, we
found that pramipexole resulted in complete disappearance
of SRED episodes for at least 10 months in our case. To our
knowledge, this is the ﬁrst paper suggesting that pramipexole
is eﬀective in a patient with SRED.
S e v e r a lo t h e rd r u g sw e r es u g g e s t e dt ob ee ﬀective against
SRED [5, 7]. The antiseizure agent topiramate is possibly the
most potent drug. In a retrospective study on 30 consecutive
patients with SRED, the data of 25 patients were available;
among these 25 subjects, 68% were considered topiramate
responders. Adverse eﬀects were reported in 84% subjects
[8]; thus, tolerability was a concern for topiramate [8, 15],
while pramipexole showed good tolerability [6].
PsychotherapyhasbeenshowntobeineﬀectiveforSRED
[5]; hence, pharmacotherapy was recommended. However,
psychological stress may develop during the course of SRED.
In our patient, SRED episodes increased during the psycho-
logically stressed period, and she had a history of depression.
Previous reports showed that stressful events were associat-
ed with the onset of SRED in approximately 16% of cases
[4, 5] and the associated psychiatric diseases were often ob-
served [5]. These observations suggest that psychotherapy is
necessary to complement the overall treatment plan, even if
psychotherapy alone cannot prevent nocturnal eating.
Another concern of SRED is hypernutrition since SRED
patients are often overweight [5]. A slight improvement in
plasma HbA1c level was observed after the improvement
of SRED episodes. However, SRED was not a key factor of
glucose control, and more eﬀorts are necessary to achieve
good control of T2DM in our patient.
The reason of discrepancy in the eﬀects of pramipexole
between previous report and our case is not clear. Triazolam
apparently worsened the SRED [5], and clonazepam ap-
peared to reduce the eﬀects of triazolam and improve SRED.
Thus, there was a possibility that a combination of dopamin-
ergic agent and clonazepam might enhance the effects. A
similar phenomenon was previously reported in which car-
bidopa/l-dopa, codeine, and clonazepam improved SRED
and had a higher response rate than monotherapy with do-
paminergic agent [5]. Psychotherapy might induce addi-
tional eﬀects on those of pharmacotherapy in our patient.
Moreover, there is a possibility that our patient is speciﬁcally
sensitive for the pramipexole treatment. Therefore, further
studies with a combination of clonazepam and pramipexole
are warranted.
This is the ﬁrst paper to report that the combination of
clonazepamandpramipexolereducedthefrequencyofSRED
episodes and RLS symptoms. Pramipexole had superior
tolerability as compared to topiramate, which is reported to
be useful in the treatment of SRED. A combination therapy
ofclonazepamandpramipexoleisrecommendedforpatients
with SRED associated with RLS as a safe trial. Pramipexole is
expectedtoimprove,atleast,parasomniaandRLSassociated
with SRED.
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